Keating and colleagues first reported the increased risk of developing CVDs like coronary heart diseases (CHD), myocardial infarction (MI), hypertension, stroke, arrhythmia, and sudden cardiac arrests in PCa patients with the use of GnRH agonists for treatment [10,42]. This evidence concerns the gene GNRH1 and posterior cortical atrophy.